The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
|Articles|December 20, 2013
Study Compares Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients
A study published by the American Journal of Pharmacy Benefits compares dose escalation patterns of patients treated with TNF blockers.
Advertisement
A new study comparing the dose escalation patterns of rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab found that etanercept users were significantly less likely to have a dose escalation. The study, published by the American Journal of Pharmacy Benefits, notes that dose escalation is associated with higher drug treatment costs and greater risk of adverse events.
To read this American Journal of Pharmacy Benefits study in its entirety, follow
Advertisement
Related to this article
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Pharmacy students can create greater career optionality by viewing the PharmD as a professional platform rather than a predetermined job title.
FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
Finerenone in Heart Failure: Evidence and Practice a Year Later
4
FDA Approves Phentolamine Eye Drop for Presbyopia in Adults
5